These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10609973)

  • 1. Predictors of individual differences in alprazolam self-medication.
    Oswald LM; Roache JD; Rhoades HM
    Exp Clin Psychopharmacol; 1999 Nov; 7(4):379-90. PubMed ID: 10609973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alprazolam-reinforced medication use in outpatients with anxiety.
    Roache JD; Stanley MA; Creson DR; Shah NN; Meisch RA
    Drug Alcohol Depend; 1997 May; 45(3):143-55. PubMed ID: 9179516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alprazolam premedication and 35% carbon dioxide vulnerability in panic patients.
    Pols H; Verburg K; Hauzer R; Meijer J; Griez E
    Biol Psychiatry; 1996 Nov; 40(9):913-7. PubMed ID: 8896779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical similarity and biological diversity in the response to alprazolam in patients with panic disorder and generalized anxiety disorder.
    Klein E; Zinder O; Colin V; Zilberman I; Levy N; Greenberg A; Lenox RH
    Acta Psychiatr Scand; 1995 Dec; 92(6):399-408. PubMed ID: 8837965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam.
    Rickels K; Pollack MH; Feltner DE; Lydiard RB; Zimbroff DL; Bielski RJ; Tobias K; Brock JD; Zornberg GL; Pande AC
    Arch Gen Psychiatry; 2005 Sep; 62(9):1022-30. PubMed ID: 16143734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder.
    Schweizer E; Patterson W; Rickels K; Rosenthal M
    Am J Psychiatry; 1993 Aug; 150(8):1210-5. PubMed ID: 8328566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in pharmacodynamics but not pharmacokinetics between subjects with panic disorder and healthy subjects after treatment with a single dose of alprazolam.
    Kaplan GB; Greenblatt DJ; Ehrenberg BL; Goddard JE; Harmatz JS; Shader RI
    J Clin Psychopharmacol; 2000 Jun; 20(3):338-46. PubMed ID: 10831021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular and symptomatic reduction effects of alprazolam and imipramine in patients with panic disorder: results of a double-blind, placebo-controlled trial.
    Taylor CB; Hayward C; King R; Ehlers A; Margraf J; Maddock R; Clark D; Roth WT; Agras WS
    J Clin Psychopharmacol; 1990 Apr; 10(2):112-8. PubMed ID: 2187912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alprazolam and diazepam on anxiety and panic attacks in panic disorder: a controlled study.
    Dunner DL; Ishiki D; Avery DH; Wilson LG; Hyde TS
    J Clin Psychiatry; 1986 Sep; 47(9):458-60. PubMed ID: 2875064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics.
    Sheehan DV; Raj AB; Harnett-Sheehan K; Dorotheo J; Sheehan MF; Trehan R; Knapp E; Swiontek A; Coleman B
    Anxiety; 1996; 2(1):40-6. PubMed ID: 9160598
    [No Abstract]   [Full Text] [Related]  

  • 12. Predictors of response to alprazolam and placebo in patients with panic disorder.
    Woodman CL; Noyes R; Ballenger JC; Lydiard RB; Sievers G; Mihalko D
    J Affect Disord; 1994 Jan; 30(1):5-13. PubMed ID: 8151049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. III. Discontinuation effects.
    Pecknold JC; Swinson RP; Kuch K; Lewis CP
    Arch Gen Psychiatry; 1988 May; 45(5):429-36. PubMed ID: 3282479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of panic disorder in older adults: a pilot study comparison of alprazolam, imipramine, and placebo.
    Sheikh JI; Swales PJ
    Int J Psychiatry Med; 1999; 29(1):107-17. PubMed ID: 10376237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls.
    Roy-Byrne PP; Cowley DS; Hommer D; Greenblatt DJ; Kramer GL; Petty F
    Psychopharmacology (Berl); 1992; 109(1-2):153-6. PubMed ID: 1365649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alprazolam, imipramine and placebo treatment of panic disorder: predicting therapeutic response.
    Rosenberg R; Bech P; Mellergård M; Ottosson JO
    Acta Psychiatr Scand Suppl; 1991; 365():46-52. PubMed ID: 1862734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased plasma cortisol level during alprazolam treatment of panic disorder: a case report.
    Fukuda M; Takazawa S; Nakagome K; Iwanami A; Hata A; Kasai K; Hiramatsu K
    Prog Neuropsychopharmacol Biol Psychiatry; 1998 Jul; 22(5):909-15. PubMed ID: 9723127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind evaluation of the safety and efficacy of abecarnil, alprazolam, and placebo in outpatients with generalized anxiety disorder. Abecarnil Work Group.
    Lydiard RB; Ballenger JC; Rickels K
    J Clin Psychiatry; 1997; 58 Suppl 11():11-8. PubMed ID: 9363043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subjective experience and attitudes towards participation in clinical trials among patients with anxiety disorders.
    Klein E; Malel D; Zilberman I; Lenox RH
    Isr J Psychiatry Relat Sci; 1997; 34(4):265-9. PubMed ID: 9409083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effect of carbamazepine.
    Klein E; Colin V; Stolk J; Lenox RH
    Am J Psychiatry; 1994 Dec; 151(12):1760-6. PubMed ID: 7977882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.